Aperam


FY23 in line; some hopes for recovery (H2 24)?

12/02/24 -"The group released an expected set of results, while it also anticipates a rather similar Q1 24 vs Q3 23. Even if the market is still depressed, particularly in Europe, a stabilisation is welcome and ..."

Pages
67
Language
English
Published on
12/02/24
You may also be interested by these reports :
12/11/25
Our target price goes down after our short-term earnings revision. Before the new EU measures come into force, which are unlikely to occur before ...

12/11/25
After the release of the group’s Q325 results, we have decided to “refresh” our valuation metrics (see the respective sections), to better account ...

11/11/25
While there have been some recent scares in the form of profit-booking for precious metals, it’s important to note that Boliden’s investment case is ...

10/11/25
The group reported anticipated results for Q325, but revised its FY downwards due to weak demand and ongoing price pressure. FY25 is “over”, and new ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO